CDK4 and breast cancer: The activity of endocrine therapy (ET), even when combined with novel targeted agents such as CDK4/6 inhibitors, PIK3CA, or mTOR inhibitors, is time-restricted, and ultimately, all metastatic BC patients treated with ET will progress.